CIK 0001737287 · Non-accelerated filer<br>Smaller reporting company
Allogene Therapeutics, Inc.
Sign in to watch- Ticker
- ALLO
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 823562771
- Phone
- (650) 457-2700
- Business address
- 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $111,656
- in 2 filings
Net −$111,656. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 47 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-05-24 | Chang David D President and CEO | Option exercise · Stock Option (Right to Buy) | −27,410 | 541,190 | ||
| 2021-05-24 | SCHMIDT ERIC THOMAS Chief Financial Officer | Option exercise | +14,897 | $18.22 | $271K | 110,994 |
| 2021-05-24 | SCHMIDT ERIC THOMAS Chief Financial Officer | Option exercise · Stock Option (Right to Buy) | −14,897 | 94,703 | ||
| 2021-05-24 | Belldegrun Arie Director | Option exercise | +379,066 | $18.22 | $6.9M | 583,034 |
| 2021-05-24 | Belldegrun Arie Director | Option exercise · Stock Option (Right to Buy) | −379,066 | 0 | ||
| 2021-05-18 | Amado Rafael EVP of R&D and CMO | Grant or award | +200,534 | 335,435 | ||
| 2021-05-18 | Bhavnagri Veer General Counsel | Option exercise | +5,000 | $2.27 | $11K | 426,353 |
| 2021-05-18 | Bhavnagri Veer General Counsel | Sale | −5,000 | $30.00 | $150K | 421,353 |
| 2021-05-18 | Bhavnagri Veer General Counsel | Option exercise · Stock Option (Right to Buy) | −5,000 | 132,300 | ||
| 2021-05-17 | Bhavnagri Veer General Counsel | Option exercise | +5,000 | $2.27 | $11K | 426,353 |
| 2021-05-17 | Bhavnagri Veer General Counsel | Sale | −5,000 | $28.30 | $141K | 421,353 |
| 2021-05-17 | Bhavnagri Veer General Counsel | Option exercise · Stock Option (Right to Buy) | −5,000 | 137,300 | ||
| 2021-04-15 | Bhavnagri Veer General Counsel | Option exercise | +10,000 | $2.27 | $23K | 431,353 |
| 2021-04-15 | Bhavnagri Veer General Counsel | Sale | −9,394 | $32.01 | $301K | 421,959 |
| 2021-04-15 | Bhavnagri Veer General Counsel | Sale | −606 | $32.64 | $20K | 421,353 |
| 2021-04-15 | Bhavnagri Veer General Counsel | Option exercise · Stock Option (Right to Buy) | −10,000 | 142,300 | ||
| 2021-03-26 | Belldegrun Arie Director | Grant or award | +53,635 | 203,968 | ||
| 2021-03-26 | Belldegrun Arie Director | Grant or award · Stock Option (Right to Buy) | +199,223 | 199,223 | ||
| 2021-03-26 | Chang David D President and CEO | Grant or award | +80,452 | 2,284,869 | ||
| 2021-03-26 | Chang David D President and CEO | Grant or award · Stock Option (Right to Buy) | +298,836 | 298,836 |
Page 12 of 18 · 348 trades